SCHEMBL723002

SCHEMBL723002

COc1cc(-c2cc3nccc(-c4c(C)noc4C)c3o2)cc(OC)c1OC

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 1/20 0.44
LMNA P02545 1/20 0.43
BRD4 O60885 10/20 0.42
BRD2 P25440 9/20 0.42
BRD3 Q15059 7/20 0.42
RAB9A P51151 1/20 0.42
PDE4C Q08493 1/20 0.42
PLK4 O00444 1/20 0.39
EP300 Q09472 1/20 0.39
BRDT Q58F21 1/20 0.39
CREBBP Q92793 1/20 0.39
CECR2 Q9BXF3 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ERN1 O75460 1/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP1B1 Q16678 1/20 0.38
SYK P43405 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL725040 0.88 PAX8 (0.47) PAX8BRD4BRD2RAB9APDE4C
SCHEMBL723093 0.84 PDE4C (0.55) BRD4PDE4CCYP1A1CYP1A2CYP1B1
SCHEMBL722271 0.84 PDE4C (0.48) BRD4PDE4CCYP1A1CYP1A2CYP1B1
SCHEMBL724908 0.84 PDE4C (0.53) BRD4PDE4CCYP1A1CYP1A2CYP1B1
SCHEMBL15210354 0.83 PDE4C (0.44) BRD4PDE4CCYP1A1CYP1A2CYP1B1
SCHEMBL723140 0.83 BRD4 (0.41) BRD4BRD2BRD3PDE4CCYP1A1
SCHEMBL723678 0.82 BRD4 (0.47) BRD4BRD2BRD3CREBBPMEN1
SCHEMBL16638610 0.81 PDE4C (0.47) BRD4PDE4CCYP1A1CYP1A2CYP1B1
SCHEMBL722596 0.81 PDE4C (0.50) BRD4PDE4CCYP1A1CYP1A2CYP1B1
SCHEMBL722839 0.80 PDE4C (0.51) BRD4PDE4CMEN1KMT2ACYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB PAX8 4624/4885LMNA 3630/4885BRD4 1150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.